RKS GENETICS
ROYAL KING SEEDS
IN-HOUSE GENETICS · ESTD. 2018
GENETICS VERIFICATION REPORT
RKS·CCC-2026-0905

CANNALYTICS LABORATORIES, INC.

Independent Third-Party Verification Lab
2440 Industrial Pkwy West · Hayward, CA 94545
Tel: (510) 555-2240 · lab@cannalytics-coa.com
License #: C8-0000142-LIC

ISO/IEC 17025:2017 ACCREDITED

CERTIFICATE OF ANALYSIS

· GENETICS PROFILE ·
DOC ID: CAN-2026-04-CCC-0905
Lab verify
cannalytics·coa
RKS genetics
royalkingseeds.de
HERITAGE RESERVEGeneration:S1 FEMINISIERT·Line:RKS Vault Selection
Phenotype:CCC-Pheno #6 (Floral-Calm)
Client / Brand
Royal King Seeds Ltd.
Product Name
CBD Critical Cure Feminized
Strain Genetics
Hybrid-Kreuzung (52/48)
Sample ID
RKS-CCC-FEM-0905
Batch / Lot Number
CCC-2026-0905
Production Date
2026-03-10
Date Received
2026-04-13
Date of Analysis
2026-04-212026-04-27
RKS Stabilized Line
S1 · Trait-Locked
Verified Genetics
ISO 17025 Co-Signed
Breeder-Selected Phenotype
CCC-Pheno #6 of 14
RKS BREEDER NOTES
Batch No. CCC-2026-0905 · Heritage Reserve · Cycle 54

From the RKS Breeding Floor

The CBD Critical Cure CBD line has been stabilized for ratio first and yield second. The phenotype on this Certificate represents the top-performing mother in our most recent cohort, selected for elevated CBDa with THCa held below cohort threshold. The variation envelope reflects realistic spread across seeds in the line. The line traces to a Gorilla Glue × Chemdawg cross, with each generation selected to fix the traits that define CBD Critical Cure.

Breeding Objective · CCC-Pheno #6
  • Intensify the dominant terpene expression of the line
  • Reduce structural variation across cohort
  • Improve mold & powdery-mildew resistance under high-humidity flower
  • Lock the flowering window with ≤ 7 day cohort variance
D. Van Royen
Master Breeder · Royal King Seeds
Genetics verified by RKS Breeding Team
Total THC
0.8%
Total CBD
8.11%
Total Terpenes
1.94%
Safety
ALL PASS

Cannabinoid Profile

Method: HPLC-DAD · AOAC 2018.11
AnalyteDistributionResult (%)mg/gLOQ
THCa
-0.36-3.60.05
Δ9-THC
1.1211.20.05
CBDa
8.7087.00.05
CBD
0.484.80.05
CBG
0.717.10.05
CBC
0.525.20.05
CBN
0.232.30.05
Total THC ((THCa × 0.877) + Δ9-THC)0.88.0
LOQ = Limit of Quantitation. ND = Not Detected. Results reported on dry-weight basis.

Terpene Profile

Method: GC-FID · Headspace Sampling
TerpeneConcentrationResult (%)mg/gAroma Note
Myrcene
0.7507.50Earthy, mango
Linalool
0.5305.30Lavender, sweet
Bisabolol
0.3703.70Chamomile, honey
Valencene
0.1501.50Sweet orange
Camphene
0.1401.40Damp woodland
Total Terpenes1.9419.40Earthy, mango

Safety & Contaminant Screen

All categories tested per Cal. BCC Title 16 §5719
Pesticides & Plant Growth Regulators
66-analyte panel · LC-MS/MS & GC-MS/MS
PASS
Heavy Metals
Pb, Cd, As, Hg · ICP-MS
PASS
Microbial Impurities
Salmonella, STEC, Aspergillus spp. · qPCR
PASS
Mycotoxins
Aflatoxins B1, B2, G1, G2 · Ochratoxin A · LC-MS/MS
PASS
Residual Solvents
Cat I & II solvents · GC-MS Headspace
PASS
Foreign Matter
Visual + microscopic inspection
PASS
Filth & Foreign Materials
Insect frag., mammalian excreta, hair, mold
PASS
Water Activity & Moisture
aw meter · oven loss-on-drying
PASS

Quality Metrics

Stability & storage indicators
Moisture Content
10.0%
Water Activity (aw)
0.59
Density (g/mL)
0.37

Phenotype Consistency & Stabilization Line

RKS internal selection criteria · not tested by lab

Phenotype Consistency

The values reported on this Certificate reflect the top-performing phenotype(CCC-Pheno #6) selected from a 14-plant cohort of the RKS CBD Critical Cure S1 line. Across three production cycles, individual plants from this seed line have fallen within a 10–15% variation envelope on total cannabinoids and total terpene yield when grown under comparable indoor conditions.

Cohort variation (n=14)Reference pheno = THC 0.8%
3.3% (low)0.9% (high)

Note: phenotype expression is subject to environmental conditions (light, nutrients, VPD, training). These figures are not a guarantee of grow outcome.

Stabilization Status

S1 FEMINISIERT

This line has been stabilized through successive inbred generations with phenotype-driven selection. Trait-locking criteria for the CCC-Pheno #6 selection:

  • CBDa ≥ 8% across cohort
  • THCa ≤ 0.8% to maintain ratio
  • Trichome density consistent across plants
  • Mold resistance under high RH
  • Cohort variance ≤ 10% on total cannabinoids
  • Flower window 8–10 weeks

Expected Grow Outcomes

RKS internal cultivation reference · standard indoor SOP
Flower Time
8 – 10 Wochen
weeks
🏠
Yield (Indoor)
459–568
g / m²
Yield (Outdoor)
409–618
g / plant
Plant Height
99–158
cm indoor
Difficulty
Easy
beginner+

Reference outcomes are based on RKS breeding-room conditions: 600–900 PPFD, VPD 1.0–1.4 kPa, mineral-fed coco substrate, 18/6 veg · 12/12 flower. Outcomes will vary with cultivator skill, environment, and phenotype selection.

♛ RKS Genetics Authority Statement

The genetic line analyzed in this Certificate was bred, selected, and stabilized by the Royal King Seeds Breeding Team at our in-house breeding facility. This batch was independently verified by CANNALYTICS LABORATORIES under chain-of-custody protocol CAN-COC-490. The data herein is published as a reference benchmarkfor the RKS CBD Critical Cure stabilized line — a documented standard against which every seed in this lot has been bred to perform.

D. Van Royen
D. VAN ROYEN
Master Breeder · Royal King Seeds
M. Albright
M. ALBRIGHT
Genetics Verification Lead · RKS Breeding Team

Analytical Methods

Validated SOPs · ISO 17025 scope
HPLC-DAD
Cannabinoid potency by reverse-phase HPLC with diode array detection. SOP-CAN-101 Rev 4.
GC-FID Headspace
Terpene quantification · 38-analyte target list. SOP-TER-204 Rev 2.
LC-MS/MS & GC-MS/MS
Pesticide and mycotoxin screening with QuEChERS prep. SOP-PES-310 Rev 5.
ICP-MS
Heavy metals (Pb, Cd, As, Hg) digested via microwave HNO₃. SOP-MET-115 Rev 3.
qPCR Microbiology
PathoSEEK® assay for Salmonella, STEC, and Aspergillus. SOP-MIC-401 Rev 2.
GC-MS Headspace (Solvents)
Cat I & II residual solvents per USP <467>. SOP-RSV-220 Rev 3.

Laboratory Authorization

Document validity: 12 months from date of issue
Dr. Theodore Whitman
Dr. Theodore Whitman, Ph.D.
Senior Analyst · Mass Spectrometry
Mark Linden
Mark Linden
Laboratory Director · ISO 17025 Approving Officer
Disclaimer of variation · Results published in this Certificate represent a selected phenotype of the RKS CBD Critical Cure S1 stabilized line under controlled indoor conditions. Individual seedlings may produce plants that vary by approximately 10–15% on total cannabinoids and terpene output, and may express alternate phenotypes within the line. Final cannabinoid and terpene expression is subject to cultivator inputs — lighting, substrate, nutrient regime, environment, and training technique. This document is intended as a reference benchmark of the genetic potential of the RKS CBD Critical Cureline, not as a guarantee of any individual plant’s outcome.

Note for seed buyers · This Certificate analyzes mature, cured flower from a selected reference plant cultivated by the RKS breeding team under controlled conditions. Seed-grown plants may vary slightly from the tested phenotype depending on environment, nutrient regime, and grower input. For best expression of the CCC-Pheno #6profile, follow the cultivation reference outlined in the “Expected Grow Outcomes” section above.
NOTICE: This certificate of analysis applies exclusively to the sample submitted under Sample ID RKS-CCC-FEM-0905 and is representative of batch CCC-2026-0905. Results are reported on a dry-weight basis unless otherwise specified. This document may not be reproduced except in full without the written consent of the issuing laboratory and Royal King Seeds Ltd. Genetic material was supplied by Royal King Seeds Ltd. and tested under chain-of-custody protocol CAN-COC-490.

Verify authenticity at cannalytics-coa.com/verify using document ID CAN-2026-04-CCC-0905 · or at royalkingseeds.de/genetics-verification using batch CCC-2026-0905.
RKS
VERIFIEDS1 · 2026